Moderna and Merck's personalized mRNA vaccine raised two-year recurrence-free survival to 82.2%, from 70% with Keytruda alone ...
A personalized cancer vaccine created from the same mRNA technology used for COVID-19 vaccines has shown 42% protection ...
The flu hospitalization rate in the U.S. is at the highest level for this time of year since the 2010 season, according to an update published Friday from the Centers for Disease Control and ...
Key takeawaysModerna stock plunged nearly 18%, wiping more than $17 billion from its market valueModerna and Merck's ...
“This is the first step,” said Dr. Robert Vonderheide, president-elect of the American Association for Cancer Research and ...
Moderna shares continued to slide on Friday (October 23, 2026), after dropping nearly 18% in the previous session, despite positive late-stage results for its p ...
12h
Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...
The field has been looking for a win and I think this one is a big one,” said Dr. Hussein Tawbi of MD Anderson Cancer Center ...
A bespoke vaccine that is tailored to target an individual's unique skin cancer reduced rates of recurrence or death in a ...
The flu hospitalization rate in the U.S. is at the highest level for this time of year since the 2010 season, according to an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results